Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALZ-801 Biomarker Effects in Early Alzheimer's Disease (APOE4 carriers)
2024-515858-25-00Phase 2Completed
- Sponsor
- Alzheon, Inc.
- Start
- Nov 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of valiltramiprosate in Alzheimer's disease (AD), sponsored by Alzheon, Inc. Primary endpoints: Primary Plasma Biomarker Outcome (core study), Key Imaging Outcome (core study) and 4 more. Started Nov 2024; status: completed.
02
Drugs
valiltramiprosate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-515858-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515858-25-00.